Skip to main content
DBVT logo

DBVT · DBV Technologies S.A.

$13.79 -0.45 (-3.16%)
Market Cap
$4.22B
Shares
296.06M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.24 Open$13.87 Day$13.84–14.58 52W$8.70–26.19 Avg vol 30d320K Short int1.5M · 0.5% float · 7.8d Short vol47% Last earningsJul 16, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 16

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Jul 16, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 15.8 · calm Equity put/call 0.46
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −22%
      below
      Price vs 50-day avg −10%
      below
      RSI (14) 44
      neutral
      MACD trend Positive
      52-week position 32%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −15%
      trailing
      6-month return −37%
      trailing
      YTD return −26%
      this year
      Relative strength −48%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $16 › 200d $18 — 200d above 50d
      Institutional flow Distributing
      16 of 72 funds reported for Jun 30 · net -41.7K sh shares · +2 new
      Insider flow Distributing
      Net -$1.3K over 90 days · 100% sells
      Short interest Rising
      0.50% of float · ▲ +13.2% MoM · 7.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      72 holders — near 3-yr high, broad support
      Squeeze score 56
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +36%
      Y/Y
      EPS growth +10%
      Y/Y
      Free cash flow $-121.7M
      Balance sheet $192.7M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 74%
      annualized · 1-yr
      Max drawdown −45%
      past year
      ATR 5.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −22% Bearish
      Price vs 50-day avg
      −10% Bearish
      RSI (14)
      44 Neutral
      MACD trend
      Positive Bullish
      52-week position
      32% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $16 › 200d $18 — 200d above 50d
      Institutional flow Distributing
      16 of 72 funds reported for Jun 30 · net -41.7K sh shares · +2 new
      Insider flow Distributing
      Net -$1.3K over 90 days · 100% sells
      Short interest Rising
      0.50% of float · ▲ +13.2% MoM · 7.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      72 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $9 Now $14 · 32% 52-wk high $26
      vs 200-day avg -22% vs 50-day avg -10%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      DBVT
      DBV Technologies S.A.
      this stock
      $4.22B -25.7% +35.8% 0.5%
      ONC
      BeOne Medicines Ltd.
      $484.13B +7.8% +22179.2% 744.4 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $122.89B +6.9% +46.2% 28.2 2.0%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $79.13B -0.2% +20.8% 19.0 3.4%
      ARGX
      Argenx SE
      $54.30B +3.2% 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      72
      % held
      7.1%
      Reported
      16 of 72
      Top holder
      MPM BIOIMPACT LLC
      Held Float
      View
      Held by Funds
      Fund positions
      11
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.5M
      Days to cover
      7.8d
      Change
      +171.6K sh
      View
      Short Volume
      Short vol %
      47%
      As of
      Aug 5, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      8.3K
      Value
      $144.5K
      As of
      Jul 8, 2026
      View
      Off-Exchange
      Off-exchange %
      39.9%
      Week of
      Jun 29, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$1.3K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $5.6M
      Net income (FY)
      $-146.9M
      EPS diluted
      $-1.05
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Sep 30, 2026
      This year
      18
      View
      Exempt Offerings
      Offering
      $306.9M
      Filed
      Apr 17, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 23, 2026
      View
      Investor Relations
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      DBVT +3.7% -15.0% -37.0% +5.5% -25.7%
      SPY +5.5% +3.3% +11.3% +3.1% +12.9%
      vs SPY -1.8% -18.3% -48.2% +2.4% -38.6%
      Key facts CIK 1613780 CUSIP 23306J309 13F (30d) 14 filings 14 filers Visit website Investor relations